A5017631516- Glioma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Acute Lymphoblastic Leukemia research
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Acute Ischemic Stroke Management
- Neuroblastoma Research and Treatments
- Meningioma and schwannoma management
- Stroke Rehabilitation and Recovery
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Neurological Complications and Syndromes
- Ultrasound and Hyperthermia Applications
- Advanced Breast Cancer Therapies
- Chromatin Remodeling and Cancer
- Cancer Treatment and Pharmacology
- Management of metastatic bone disease
Memorial Sloan Kettering Cancer Center
2017-2025
Cornell University
2020-2024
Weill Cornell Medicine
2021-2023
Stanford University
2023
Yale University
2023
Columbia University Irving Medical Center
2014-2020
Neurology, Inc
2020
Columbia University
2013-2016
NewYork–Presbyterian Hospital
2016
Texas Health Dallas
2016
Abstract Background Leptomeningeal metastases (LM) are associated with limited survival and treatment options. While involved-field radiotherapy is effective for local palliation, it lacks durability. We evaluated the toxicities of proton craniospinal irradiation (CSI), a encompassing entire central nervous system (CNS) compartment, patients LM from solid tumors. Methods enrolled to receive hypofractionated CSI in this phase I prospective trial. The primary endpoint was describe...
2501 Background: MTX-based chemoradiotherapy is effective in PCNSL, but carries a risk of severe neurotoxicity (NT), especially the elderly. In phase II single arm study, R-MPV-A chemotherapy was combined with substantially reduced doses radiotherapy (23.4 Gy), achieving prolonged progression free survival (PFS) and overall (OS) acceptable NT. Because had never been tested without radiotherapy, we conducted randomized study to determine if low radiation played role observed disease control,...
Abstract Background Contemporary outcomes and relapse patterns in primary CNS lymphoma (PCNSL) are lacking. We analyzed factors associated with a large cohort extensive follow-up. Methods T1-post-contrast-enhancing disease was characterized immunocompetent PCNSL (diffuse B-cell) patients from 1983 to 2020. Patients were stratified by response induction consolidation (complete/unconfirmed [CR/CRu], partial, stable, progression [POD]). Refractory POD during (or ≤3 months of) induction. Initial...
Abstract Purpose: Ibrutinib is a first-in-class inhibitor of Bruton tyrosine kinase. We previously reported the safety and short-term antitumor activity ibrutinib in 20 patients with relapsed or refractory (r/r) primary central nervous system (CNS) lymphoma (PCNSL) secondary CNS (SCNSL). Patients Methods: enrolled 26 additional r/r PCNSL/SCNSL into dose-expansion cohort trial combined 46 (31 PCNSL 15 SCNSL). received at 560 840 mg daily dose-escalation expansion cohort. The median follow-up...
Primary CNS lymphoma (PCNSL), a rare malignancy, is usually treated with high-dose methotrexate in the first-line setting, typically followed by consolidation therapy. Due to broad range of currently available treatments for PCNSL, comparability long-term follow-up studies limited, and data are scattered across small studies.
Abstract Background High-dose methotrexate (HD-MTX) has broad use in the treatment of central nervous system (CNS) malignancies but confers significant toxicity without inpatient hydration and monitoring. Glucarpidase is a bacterial recombinant enzyme dosed at 50 units (u)/kg, resulting rapid systemic MTX clearance. The aim this study was to demonstrate feasibility low-dose glucarpidase facilitate clearance patients with CNS lymphoma (CNSL). Methods Eight CNSL received HD-MTX 3 or 6 g/m 2...
To report the tolerability and efficacy of olaparib with temozolomide (TMZ) for glioma.Single-center retrospective series patients glioma treated olaparib/TMZ from September 2018 to December 2021.Twenty (median age: 42 years, median Karnofsky Performance Status: 90) received diagnoses IDH-mutant oligodendroglioma (n = 5), astrocytoma grade 2-3 4), 4 7), or IDH-wildtype 4). One patient was upfront 19 at recurrence 3). Olaparib 150 mg administered 3 times/week concurrent TMZ 50-75 mg/m2 daily....
We describe video electroencephalography (video-EEG) correlates of transient neurological attacks due to plateau waves—paroxysmal elevations in intracranial pressure—in patients with leptomeningeal metastases. identified 3 metastases, hypertension, and captured on video-EEG without evidence seizures or epileptiform activity. all clinical events reviewed the corresponding EEG data for abnormalities. All had mild moderate slowing 2 frontal intermittent rhythmic delta activity during background...
Proton craniospinal irradiation (pCSI) is a promising treatment for patients with solid tumor leptomeningeal metastasis (LM). We hypothesize that genetic characteristics before and changes resulting after pCSI will reflect clinical response to pCSI. analyzed the cerebrospinal fluid (CSF) circulating DNA (ctDNA) from receiving LM explored variations associated response.We subjected CSF 14 cell-free sequencing using targeted-sequencing panel. In parallel, plasma ctDNA primary tumors were...
The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, approximately 50% patients relapse or become refractory within 1 year. Prognosis following is dismal no standard salvage therapy exists. Bruton's tyrosine kinase (BTK), a key regulator the B-cell receptor (BCR) pathway, emerged as promising therapeutic target. first BTK inhibitor ibrutinib been...
PURPOSE High-dose methotrexate (HD-MTX) is the backbone of curative therapy for CNS lymphoma. Because toxicity, MTX administered in inpatient setting along with hyperhydration and monitoring until clearance documented (3-5 days). Frequent hospitalizations result patient time away from work, home, exposure to potential iatrogenic/nosocomial complications. Here, we aim demonstrate feasibility HD-MTX administration outpatient low-dose glucarpidase facilitating clearance. METHODS This a...